This week, Novartis Gene Therapies released an SMA community statement detailing the progress on enrollment for both STEER and STRENGTH clinical trials, their
investigational intrathecal (IT) OAV101 studies.
![Novartis-Logo Novartis-Logo](https://www.curesma.org/wp-content/uploads/2019/07/Novartis-Logo.png)
This week, Novartis Gene Therapies released an SMA community statement detailing the progress on enrollment for both STEER and STRENGTH clinical trials, their
investigational intrathecal (IT) OAV101 studies.
Help make a difference in the lives of people affected by spinal muscular atrophy.